When does Cellectis (ALCLS.PA) report earnings?

Cellectis S.A. is scheduled to report on **19 Mar 2026**. Expect updates on cash runway, R&D spending, and clinical programme timelines that typically move the stock intraday.

What is Meyka AI's short-term forecast for ALCLS.PA stock?

Meyka AI's forecast model gives a monthly target of **€3.30**, a quarterly target of **€4.06**, and a 12‑month target of **€5.60**, with model-based caveats and no guarantees.

How risky is ALCLS.PA stock ahead of earnings?

Risk is high; the company is clinical-stage with negative EPS and event-driven volatility. Key risks are trial setbacks or cash-burn surprises, while positive readouts can sharply re-rate the stock.

What valuation metrics should investors watch for ALCLS.PA stock?

Watch EPS **-0.28**, price-to-sales **3.43**, price-to-book **3.56**, current ratio **1.49**, and debt to equity **0.92** for a snapshot of valuation and balance-sheet stress.

EU Stocks

Earnings due 19 Mar 2026: ALCLS.PA Cellectis S.A. on EURONEXT — catalyst ahead

ByDanny Kontos March 17, 2026March 17, 2026

We track ALCLS.PA stock ahead of Cellectis S.A.’s scheduled earnings on 19 Mar 2026. The share trades intraday at €3.21 (+1.75%), range €3.08–€3.24, with volume 82,140 versus average 263,794. Investors will watch clinical updates and cash runway commentary; biotech catalysts usually move price sharply on results or guidance. We summarise the near-term setup, valuation, technicals, and model-driven forecasts to frame trading and investment decisions.